Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 21, 2008

View Archived Issues

Extended-release hydrocodone/acetaminophen improves pain, function in osteoarthritis patients

SAR-113945 shows potential for osteoarthritic joint pain

Novel CB1 receptor antagonist profiled at Bristol-Myers Squibb

Telik enters into diabetes license agreement with ReceptorBio

Vertex initiates phase III REALIZE trial with telaprevir in HCV

Vion plans to conduct a phase III trial of Cloretazine in combination with AML and MDS therapy

Recent patent literature divulges novel treatment options for diabetes

New compounds for pulmonary hypertension reported in recent Concert patent

New treatments for autoimmune disorders disclosed in recent patents

4SC describes new compounds for urinary incontinence in recent patent

sc28AT potentiates tacrolimus effect on acute kidney allograft rejection in baboons

TY-027: a novel approach to treating neuropathic pain

Melior collaborates with AstraZeneca using theraTRACE discovery platform

Boehringer Ingelheim and Ablynx extend research collaboration in AD

Lilly completes acquisition of SGX

Noven enters license agreement with Procter & Gamble for HSDD patches

RegeneRx completes patient enrollment in phase II RGN-137 trial

Activx reports topline results from phase Ib and phase IIa clinical trials of KRP-1

EMEA accepts for review Arpida's MAA for intravenous iclaprim in cSSTI

Enobia begins testing of enzyme replacement therapy for hypophosphatasia

Dual P2X3/P2X2/3 purinergic receptor antagonists profiled at Roche

NovaRx initiates pivotal phase III trial for Lucanix in lung cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...